About the company
Rocket Pharmaceuticals Inc is a leading clinical-stage biopharmaceutical company that is dedicated to the development of innovative gene therapies for rare and devastating pediatric diseases. With a commitment to transforming the lives of patients and their families, Rocket Pharma is at the forefront of pioneering medical advancements. One of the company's pipeline products is RP-A501, which holds great promise for treating Danon Disease. Danon Disease is a rare genetic disorder characterized by the accumulation of glycogen in muscle and cardiac tissue, leading to severe muscle weakness and heart problems. RP-A501 aims to address the underlying cause of the disease by delivering a functional copy of the LAMP2B gene, thereby improving muscle function and preventing the progression of cardiac complications. Another promising therapy in Rocket Pharma's pipeline is RP-L102, designed for the treatment of Fanconi Anemia (FA). FA is a rare inherited blood disorder characterized by bone marrow failure, increased risk of cancer, and developmental abnormalities. RP-L102 utilizes a lentiviral vector to deliver a healthy copy of the Fanconi Anemia complementation group A (FANCA) gene into the patient's cells, potentially restoring proper DNA repair mechanisms and halting disease progression. RP-L201 is another exciting gene therapy being developed by Rocket Pharma. This therapy holds potential in addressing Leukocyte Adhesion Deficiency Type 1 (LAD-I), a rare immunodeficiency disorder that impairs the body's ability to fight infections. RP-L201 aims to correct the deficiency by introducing a functional copy of the ITGB2 gene, enhancing the adhesion and migration of immune cells to infected sites, and improving the patient's immune response. Rocket Pharma's pipeline also includes RP-L301, a gene therapy candidate for Pyruvate Kinase Deficiency (PKD). PKD is a rare inherited disorder that affects red blood cells, leading to chronic anemia and a range of associated complications. RP-L301 aims to restore proper red blood cell metabolism by delivering a functional copy of the Pyruvate Kinase (PK) gene, thus potentially providing a long-term therapeutic solution for PKD patients. Additionally, Rocket Pharma is developing RP-L401 for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare and severe disorder characterized by abnormal bone growth, bone marrow failure, and other complications. RP-L401 leverages a lentiviral vector to introduce a functional copy of the TCIRG1 gene into the patient's cells, potentially improving bone remodeling, reducing bone marrow abnormalities, and enhancing overall health outcomes for IMO patients. Rocket Pharmaceuticals Inc continues to make significant strides in its quest to revolutionize the treatment landscape for rare pediatric diseases. By harnessing the power of gene therapy, the company's pipeline products have the potential to provide much-needed hope and transformative outcomes for patients and their families who face these devastating conditions. With a passionate team and a dedication to pioneering research, Rocket Pharma is poised to make a lasting impact in the field of rare disease therapeutics.
Website: https://www.rocketpharma.com
Data updated: June 2, 2026
